IPP Bureau
Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US
By IPP Bureau - August 17, 2023
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Cipla launches knowledge sharing platform ‘Ciplamed 2.0’
By IPP Bureau - August 16, 2023
CiplaMed 2.0 leverages advanced analytics and automation
SSI Strategy to acquires NDA Group partner to form global life sciences consultancy
By IPP Bureau - August 16, 2023
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations
By IPP Bureau - August 16, 2023
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP
By IPP Bureau - August 16, 2023
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
Mobile addicted generation heading towards hearing disorders: Survey
By IPP Bureau - August 16, 2023
The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group
CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests
By IPP Bureau - August 16, 2023
CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma
By IPP Bureau - August 16, 2023
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Tulasi Healthcare Introduces dTMS Therapy service for Treatment-Resistant Depression
By IPP Bureau - August 16, 2023
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Exor to buy 15% shareholding in Philips
By IPP Bureau - August 16, 2023
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
BioNTech appointing James Ryan as Chief Legal Officer
By IPP Bureau - August 16, 2023
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat
By IPP Bureau - August 16, 2023
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Dr Srikanth Ramaswamy bags Lister Prize to fund brain research
By IPP Bureau - August 16, 2023
Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize
Parexel and Partex collaborate to leverage on AI and Big Data to accelerate drug delivery
By IPP Bureau - August 16, 2023
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Eugia Pharma receives USFDA Approval for Icatibant Injection
By IPP Bureau - August 16, 2023
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
